Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work.

Robinson M. et al, (2019), J Pathol Clin Res, 5, 91 - 99

Training and accreditation standards for pathologists undertaking clinical trial work.

Rees G. et al, (2019), J Pathol Clin Res, 5, 100 - 107

The Use of Digital Pathology and Image Analysis in Clinical Trials

Pell R. et al, (2019), The Journal of Pathology: Clinical Research

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

Plummer ER. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Banerji U. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37

Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation

Blagden SP. et al, (2019), MOLECULAR CANCER THERAPEUTICS, 18

NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.

Evans TRJ. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37

OVPSYCH2: A randomised study of psychological support following chemotherapy for ovarian cancer

Howells L. et al, (2019), PSYCHO-ONCOLOGY, 28, 6 - 6

Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer

Blagden SP. et al, (2018), Clinical Cancer Research, clincanres.2277.2018 - clincanres.2277.2018

Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors

(2018), Annals of Oncology

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.

Brown NF. et al, (2018), Neuro-oncology, 20, 1634 - 1642

A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies.

Blagden S. et al, (2018), Ann Oncol, 29 Suppl 8

OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer.

Blagden S. et al, (2018), Ann Oncol, 29 Suppl 8, viii333 - viii334

Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment.

Clamp AR. et al, (2018), Ann Oncol, 29 Suppl 8

Anti-tumor activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

BLAGDEN S. et al, (2018), British Journal of Cancer

Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.

Blagden S. et al, (2018), Wiley interdisciplinary reviews. RNA, 9

Genome-scale CRISPR/Cas9 screen identifies factors required for sensitivity to pyrimidine nucleoside analogs

Sarr A. et al, (2018), CANCER RESEARCH, 78

NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.

Blagden SP. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36

QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY

Blagden SP. et al, (2017), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27, 1919 - 1919

QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY

Blagden SP. et al, (2017), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 27, 14 - 14